89 related articles for article (PubMed ID: 12797396)
21. Strategies to improve the killing of tumors using temozolomide: targeting the DNA repair protein MGMT.
Jiang G; Li LT; Xin Y; Zhang L; Liu YQ; Zheng JN
Curr Med Chem; 2012; 19(23):3886-92. PubMed ID: 22788764
[TBL] [Abstract][Full Text] [Related]
22. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Yamauchi T; Ogawa M; Ueda T
Mol Pharmacol; 2008 Jul; 74(1):82-91. PubMed ID: 18430789
[TBL] [Abstract][Full Text] [Related]
23. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.
Hirose Y; Kreklau EL; Erickson LC; Berger MS; Pieper RO
J Neurosurg; 2003 Mar; 98(3):591-8. PubMed ID: 12650433
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Barvaux VA; Lorigan P; Ranson M; Gillum AM; McElhinney RS; McMurry TB; Margison GP
Mol Cancer Ther; 2004 Oct; 3(10):1215-20. PubMed ID: 15486188
[TBL] [Abstract][Full Text] [Related]
25. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Hermisson M; Klumpp A; Wick W; Wischhusen J; Nagel G; Roos W; Kaina B; Weller M
J Neurochem; 2006 Feb; 96(3):766-76. PubMed ID: 16405512
[TBL] [Abstract][Full Text] [Related]
26. Triazene compounds: mechanism of action and related DNA repair systems.
Marchesi F; Turriziani M; Tortorelli G; Avvisati G; Torino F; De Vecchis L
Pharmacol Res; 2007 Oct; 56(4):275-87. PubMed ID: 17897837
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Liu L; Taverna P; Whitacre CM; Chatterjee S; Gerson SL
Clin Cancer Res; 1999 Oct; 5(10):2908-17. PubMed ID: 10537360
[TBL] [Abstract][Full Text] [Related]
28. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
29. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.
Hirose Y; Berger MS; Pieper RO
Cancer Res; 2001 Mar; 61(5):1957-63. PubMed ID: 11280752
[TBL] [Abstract][Full Text] [Related]
30. DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system.
Caporali S; Falcinelli S; Starace G; Russo MT; Bonmassar E; Jiricny J; D'Atri S
Mol Pharmacol; 2004 Sep; 66(3):478-91. PubMed ID: 15322239
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
[TBL] [Abstract][Full Text] [Related]
32. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Cai S; Xu Y; Cooper RJ; Ferkowicz MJ; Hartwell JR; Pollok KE; Kelley MR
Cancer Res; 2005 Apr; 65(8):3319-27. PubMed ID: 15833865
[TBL] [Abstract][Full Text] [Related]
35. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients.
D'Atri S; Piccioni D; Castellano A; Tuorto V; Franchi A; Lu K; Christiansen N; Frankel S; Rustum YM; Papa G
Ann Oncol; 1995 Apr; 6(4):389-93. PubMed ID: 7619755
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological strategies to increase the antitumor activity of methylating agents.
Tentori L; Graziani G
Curr Med Chem; 2002 Jul; 9(13):1285-301. PubMed ID: 12052167
[TBL] [Abstract][Full Text] [Related]
37. Involvement of the mismatch repair system in temozolomide-induced apoptosis.
D'Atri S; Tentori L; Lacal PM; Graziani G; Pagani E; Benincasa E; Zambruno G; Bonmassar E; Jiricny J
Mol Pharmacol; 1998 Aug; 54(2):334-41. PubMed ID: 9687575
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
[TBL] [Abstract][Full Text] [Related]
39. Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells.
D'Atri S; Graziani G; Lacal PM; Nisticò V; Gilberti S; Faraoni I; Watson AJ; Bonmassar E; Margison GP
J Pharmacol Exp Ther; 2000 Aug; 294(2):664-71. PubMed ID: 10900246
[TBL] [Abstract][Full Text] [Related]
40. Recent approaches to improve the antitumor efficacy of temozolomide.
Tentori L; Graziani G
Curr Med Chem; 2009; 16(2):245-57. PubMed ID: 19149575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]